Advertisement
UK markets close in 7 hours 17 minutes
  • FTSE 100

    8,177.51
    -13.78 (-0.17%)
     
  • FTSE 250

    20,410.06
    +0.13 (+0.00%)
     
  • AIM

    778.17
    -0.15 (-0.02%)
     
  • GBP/EUR

    1.1853
    +0.0026 (+0.22%)
     
  • GBP/USD

    1.2730
    +0.0021 (+0.16%)
     
  • Bitcoin GBP

    51,260.27
    -387.15 (-0.75%)
     
  • CMC Crypto 200

    1,388.86
    +51.11 (+3.82%)
     
  • S&P 500

    5,487.03
    +13.80 (+0.25%)
     
  • DOW

    38,834.86
    +56.76 (+0.15%)
     
  • CRUDE OIL

    81.31
    -0.26 (-0.32%)
     
  • GOLD FUTURES

    2,347.90
    +1.00 (+0.04%)
     
  • NIKKEI 225

    38,570.76
    +88.65 (+0.23%)
     
  • HANG SENG

    18,427.49
    +511.94 (+2.86%)
     
  • DAX

    18,113.39
    -18.58 (-0.10%)
     
  • CAC 40

    7,621.52
    -7.28 (-0.10%)
     

Compared to Estimates, Alcon (ALC) Q1 Earnings: A Look at Key Metrics

Alcon (ALC) reported $2.44 billion in revenue for the quarter ended March 2024, representing a year-over-year increase of 4.8%. EPS of $0.78 for the same period compares to $0.70 a year ago.

The reported revenue represents a surprise of -0.64% over the Zacks Consensus Estimate of $2.46 billion. With the consensus EPS estimate being $0.72, the EPS surprise was +8.33%.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

ADVERTISEMENT

Here is how Alcon performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

  • Net sales by region- United States: $1.15 billion versus $1.08 billion estimated by two analysts on average.

  • Net sales by region- International: $1.30 billion versus the two-analyst average estimate of $1.37 billion.

  • Net Sales- Total Surgical: $1.34 billion versus the four-analyst average estimate of $1.35 billion. The reported number represents a year-over-year change of +2.6%.

  • Net Sales- Total Vision care: $1.11 billion versus the four-analyst average estimate of $1.09 billion. The reported number represents a year-over-year change of +5.5%.

  • Net Sales- Total Surgical- Consumables: $686 million versus the four-analyst average estimate of $685.88 million. The reported number represents a year-over-year change of +4.6%.

  • Revenues- Other revenues: $15 million versus the four-analyst average estimate of $15.46 million.

  • Net Sales- Total Vision Care- Contact lenses: $671 million compared to the $643.96 million average estimate based on four analysts. The reported number represents a change of +9.1% year over year.

  • Net Sales- Total Vision Care- Ocular health: $435 million versus $442.54 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +5.1% change.

  • Net Sales- Total Surgical- Implantables: $433 million versus $439.48 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +1.4% change.

  • Net Sales- Total Surgical- Equipment/other: $219 million versus the four-analyst average estimate of $223.70 million. The reported number represents a year-over-year change of -0.9%.

View all Key Company Metrics for Alcon here>>>

Shares of Alcon have returned +0.9% over the past month versus the Zacks S&P 500 composite's +1.3% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Alcon (ALC) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research